Bryan Griffin Email & Phone Number

Northeast

Responsible for leading a contracting team to negotiate, pull through and manage health systems for the plasma portfolio including immunoglobulin, albumin and alpha one products. The geography covers PA to ME.

Greater New York City Area

2019/2020 Senior Regional Business Director of the YearLed a team of 9 high performing sales professionals from North Carolina to New York in the rare disease space. Formerly managed a team from Maine to New York in the same division (Immunology and HAE) and at times, have covered the entire East Coast. Takeda purchased Shire and this role is a continuation of what I have been doing since 2016.

Northeast (New York To Maine)

Responsible for the management and performance of 8 territories through the Northeast. My team focuses on partnering with leaders within the Primary Immune Deficiency community. This includes, but is not limited to physicians (immunology based), specialty pharmacies and the patients themselves. Please note, Baxter split and became Baxalta. Shire then purchased Baxalta. Takeda then purchased Shire. The roles from 2016 have been within the same business unit with expanding responsibilities, geographies and product lines.

New York (New York To Boston)

Please note, Shire purchased Baxalta. Promoted to Senior Regional Business Director and responsible for leading a team of Immunology Business Managers (IBM's) between New York and Boston in the rare disease space. One side of this team is responsible for the Shire line of products for Primary Immune Deficiency (PI) and the other for Hereditary Angioedema (HAE). The PI team is responsible for the continued launch of 2 subcutaneously infused products while the HAE team launched a first in class monoclonal antibody with unprecedented success.

New York City To Montauk

Baxter split on July 1 2015 and the Bioscience team I worked on morphed into Baxalta. I was named a Next Generation Leader after a run of highly successful years, including the launch of a once a month, subcutaneous immunoglobulin product. The position above is a continuation of my role at Baxter negotiating with healthcare systems and critical hospitals through the New York area. At the end of my tenure in this position I was named to the Emerging Leaders Development Program and ultimately promoted to Regional Business Director for the Northeast Immunology Team. 2016: -Emerging Leader Development Team-Leveled to ABMIII-Regional Trainer2015:-Next Generation Leader Team-Presidents Club-Regional Trainer-113.7% Gammagard-112.3% Hyqvia-4th overall

Greater New York City Area, Boroughs, Long Island

IVIG and Albumin account manager in the hospital setting. Specifically focused on large healthcare systems and corresponding corporate offices, university hospitals, oncology centers, transplant centers as well as large alternate infusion sites and non-reporting specialty pharmacies. I work closely with pharmacists, buyers, hospital/system administrators and whomever makes purchasing/product decisions. At the end of 2014, I was responsible for the launch of a subcutaneous immunoglobulin product. 2014-Sales Advisory Board-106.4% Gammagard- ~170% Flexbumin (2nd overall <1%)2013-102.2% Gammagard (5th overall)-229.4% Flexbumin (1st overall, 8,834 units over quota)

New York (Manhattan-Montauk)

I promoted and sold two products for Alpha-1 Antitrypsin Deficiency (genetic emphysema) which is a rare and uncommon genetic deficiency originating in the liver and often causing emphysema. The products are human proteinase inhibitors which augment Alpha-1 levels in the blood to prevent the degradation of neutrophil elastase. I worked closely with pulmonologists, transplant specialists, allergists, immunologists and internists in both the hospital and private office setting. Furthermore, I worked with the non-profit organizations who assisted patients affected by this disease state which include both the Alpha One Foundation and COPD Foundation.

New York

I promoted and sold a monoclonal antibody which inhibited exacerbations in patients affected by allergic asthma. The product would bind to IgE preventing allergens from triggering asthmatic responses. The drug was provided through a specialty pharmacy system and administered through monthly injections in hospitals, pulmonary/allergy/immunology/internist offices.-Management Development Program (Top 5% of reps over 3 years)-Led Specialty Sales Workshop 2 as a Breakout Leader-Mentorship of 2 new hires

New York

Sold four different blood pressure medications to cardiologists, pulmonologists and internists, launching two which were first in class.-2nd Rookie of the Year rankings (2007)-Long Island Executive Council Member (1 rep per district)-Published in Novartis Journal (Incentives E-Newsletter 2008)-Pod Quarterback (2008-2009)-Top Pod in Nation (2008)-Sales Impact Award (2007)-Collaboration and Teamwork Award (4x's)

Plainview, New York

Group Sales and Marketing

Foxboro, Ma

Head intern in charge of in-game and on-field promotions. Also gained experience performing basic sales tasks for senior executives.